BioSpace News Archive

Albert Einstein College of Medicine researchers have been awarded a five-year, $3.5 million grant from the National Institutes of Health to study the effects of COVID-19 on the brains of adults who had mild or asymptomatic infection.

Aesthetic Devices Market report puts a light on primary and secondary drivers, market share, leading segments, possible sales volume, and geographical analysis.

Medison Pharma is pleased to announce the approval of KIMMTRAK® by Health Canada and Therapeutics Goods Administration for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the eye.

Element Biosciences, Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, announced it has shipped multiple AVITI systems to its first set of customers.

PathAI To Present Three Abstracts at International Liver Congress 2022.

Interim results from the DREAM trial showed treatment with Somryst, a prescription digital therapeutic (PDT) for patients with chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity through six months.

The PPD clinical research business of Thermo Fisher Scientific has been named Clinical Research Company of the Year at the 2022 PharmaTimes Clinical Researcher of the Year International competition held recently in London.

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will be participating in a fireside chat at the JMP Securities Life Sciences Conference being held in New York on June 15 – 16, 2022.

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it received written notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with the Nasdaq minimum bid price.